Dr Bo Gao:
Dr Bo Gao is a medical oncologist and clinical researcher at Blacktown and Westmead Hospitals. She completed a PhD in ovarian cancer in 2013 and her main clinic interests are in lung, head and neck, and ovarian cancers. She has led multiple clinical studies in these tumour groups and is also involved in studies of new cancer drugs (Phase 1 studies). She maintains a leadership role in the clinical trial unit at Blacktown Hospital.
A/Prof Matt Carlino:
Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals, a Clinical Associate Professor at The University of Sydney, and a Faculty Member at Melanoma Institute Australia. He has a research interest in examining biomarkers of response and resistance to both targeted and immunotherapy treated metastatic melanoma and undertook his PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.
He continues to be involved in the translational research program based at the melanoma institute and the Westmead centre for medical research. He is an investigator on multiple Phase I,II and III clinical trials in melanoma and other solid tumours.
Dr Mark Wong:
Dr Mark Wong is a senior medical oncologist at Blacktown and Westmead Hospitals and clinical senior lecturer at the University of Sydney. His research focuses on therapeutic drug monitoring and pharmacogenetics of targeted therapies. He has been an investigator on over 30 clinical studies. His main clinical interest is in CNS and gastrointestinal cancers.
Mr Raymond Tangunan:
Raymond Tangunan has been the Clinical Trials Manager of Blacktown Cancer and Haematology Centre – Medical Oncology since February 2016. He was previously Assistant Manager at The Crown Princess Mary Cancer Centre Medical Oncology Clinical Trials Unit. He has been working in oncology trials for 12 years.
A/Prof Adnan Nagrial:
Associate Professor Adnan Nagrial is a medical oncologist and early-career researcher at Westmead and Blacktown Hospitals. He has a research interest in novel cancer therapeutics and completed a PhD investigating biomarkers of therapeutic efficacy in pancreas cancer. His clinical interest is in solid tumour oncology, particularly lung cancers, mesothelioma, colorectal cancer and all other gastrointestinal cancers (oesophageal, gastric, pancreatic, hepatocellular, biliary tract, neuroendocrine). His clinical research focuses on trials in these tumour types and includes early phase cancer drug development, especially in the area of immuno-oncology drugs. He has been an investigator on >25 clinical studies.